Your browser doesn't support javascript.
loading
Is Additional Surgery Always Sufficient for Preventing Recurrence After Endoscopic Submucosal Dissection with Curability C-2 for Early Gastric Cancer?
Hatta, Waku; Gotoda, Takuji; Oyama, Tsuneo; Kawata, Noboru; Takahashi, Akiko; Oka, Shiro; Hoteya, Shu; Nakagawa, Masahiro; Hirano, Masaaki; Esaki, Mitsuru; Matsuda, Mitsuru; Ohnita, Ken; Shimoda, Ryo; Yoshida, Motoyuki; Dohi, Osamu; Takada, Jun; Tanaka, Keiko; Yamada, Shinya; Tsuji, Tsuyotoshi; Ito, Hirotaka; Aoyagi, Hiroyuki; Nakamura, Tomohiro; Nakaya, Naoki; Shimosegawa, Tooru; Masamune, Atsushi.
Afiliação
  • Hatta W; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Gotoda T; Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. takujigotoda@yahoo.co.jp.
  • Oyama T; Division of Endoscopy, Saku Central Hospital Advanced Care Center, Saku, Japan.
  • Kawata N; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Takahashi A; Division of Endoscopy, Saku Central Hospital Advanced Care Center, Saku, Japan.
  • Oka S; Department of Gastroenterology and Metabolism, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
  • Hoteya S; Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan.
  • Nakagawa M; Department of Endoscopy, Hiroshima City Hospital, Hiroshima, Japan.
  • Hirano M; Department of Internal Medicine, Niigata Prefectural Central Hospital, Joetsu, Japan.
  • Esaki M; Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Matsuda M; Department of Gastroenterology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
  • Ohnita K; Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
  • Shimoda R; Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.
  • Yoshida M; Department of Internal Medicine and Gastrointestinal Endoscopy, Saga Medical School, Saga, Japan.
  • Dohi O; Department of Gastroenterology and Endocrinology and Metabolism, Nara Medical University, Nara, Japan.
  • Takada J; Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Tanaka K; Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Yamada S; Department of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Tsuji T; Department of Gastroenterology and Hepatology, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Ito H; Department of Gastroenterology, Akita City Hospital, Akita, Japan.
  • Aoyagi H; Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Japan.
  • Nakamura T; Division of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan.
  • Nakaya N; Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Sendai, Japan.
  • Shimosegawa T; Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Sendai, Japan.
  • Masamune A; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ann Surg Oncol ; 26(11): 3636-3643, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31342376
ABSTRACT

BACKGROUND:

When a lesion does not meet the curative criteria of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), referred to as non-curative resection or curability C-2 in the guidelines, an additional surgery is the standard therapy because of the risk of lymph node metastasis (LNM).

OBJECTIVE:

This study aimed to identify high-risk patients for recurrence after additional surgery for curability C-2 ESD of EGC.

METHODS:

This multicenter retrospective cohort study enrolled 1064 patients who underwent additional surgery after curability C-2 ESD for EGC. We evaluated the recurrence rate and the risk factors for recurrence after additional surgery in these patients.

RESULTS:

The 5-year recurrence rate after additional surgery was 1.3%. Multivariate Cox analysis revealed that the independent risk factors for recurrence after additional surgery were LNM (hazard ratio [HR] 32.47; p < 0.001) and vascular invasion (HR 4.75; p = 0.014). Moreover, patients with both LNM and vascular invasion had a high rate of recurrence after additional surgery (24.6% in 5 years), with a high HR (119.32) compared with those with neither LNM nor vascular invasion. Among patients with no vascular invasion, a high rate of recurrence was observed in those with N2/N3 disease according to the American Joint Committee on Cancer TNM staging system (27.3% in 5 years), in contrast with no recurrence in those with N1 disease.

CONCLUSIONS:

Patients with both LNM (N1-N3) and vascular invasion, as well as those with N2/N3 disease but no vascular invasion, would be candidates for adjuvant chemotherapy after additional surgery for curability C-2 ESD of EGC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Ressecção Endoscópica de Mucosa / Recidiva Local de Neoplasia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Ressecção Endoscópica de Mucosa / Recidiva Local de Neoplasia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article